Precipio Inc (PRPO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$25.60-6.06%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Intact: The reason to own it still holds.
Precipio is growing revenue with a target of at least $24 million in 2025. The company is stabilizing management and advancing its cancer diagnostic products. Analysts expect revenue growth near 39% next year, showing market confidence in recovery.
Precipio is still loss-making and faces margin challenges. The recent 22% drop from its high shows investor concerns. If revenue growth slows below expectations, the turnaround may stall.
The stock price is about 52% below our valuation level, reflecting high risk. The market expects 39% revenue growth next year, which aligns with analyst forecasts, but the company must deliver to avoid further declines.
Breaks if: significant management turnover or disruption occurs
Breaks if: losses widen or margins fail to improve by FY26
annual revenue falls below $24 million in 2025
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. PRPO is currently loss-making but has shown some revenue growth and management stability, which supports the ongoing thesis despite elevated risks.
The market appears to price PRPO as justified, with a low expectations gap compared to peers. It is considered cheap relative to its industry, suggesting that investors may not be fully accounting for its potential growth.
Management is focused on increasing revenue and achieving adjusted EBITDA profitability, with recent results showing a 30% revenue increase year-over-year. However, operating income has been volatile, indicating mixed progress towards reducing net losses.
The future trajectory of PRPO will depend on management's ability to maintain revenue growth and improve profitability. Additionally, broader sector performance, particularly from key players, will influence investor sentiment and company performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company achieved profitability and revenue growth. Record revenue and positive EBITDA support growth objectives. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, PRPO's outlook will be shaped by its operational execution and market conditions. Not investment advice.